Furthermore, the similarity between the mast cell activation syndrome and LHCS has been observed, and many consider post-COVID-19 to be a variant of the mast cell activation syndrome. The symptom set of LHCS in the majority of cases is very similar to the chronic inflammatory response syndrome (CIRS)/myalgic encephalomyelitis/chronic fatigue syndrome, although in LHCS, symptoms tend to improve slowly in the majority of the cases. A puzzling feature of the LHCS syndrome is that it is not predicted by initial disease severity post-COVID-19 frequently affects mild-to-moderate cases and younger adults that did not require respiratory support or intensive care. LHCS is not only seen after the COVID-19 infection but it is being observed in some people that have received vaccines (likely due to monocyte activation by the spike protein from the vaccine). The incidence of symptoms after COVID-19 varies from as low as 10% to as high as 80%. The Long Haul COVID-19 Syndrome (LHCS) is an often debilitating syndrome characterized by a multitude of symptoms such as prolonged malaise, headaches, generalized fatigue, sleep difficulties, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction. Press Conference on Ivermectin (Dec 4, 2020).Lecture: Ivermectin and COVID-19 (Jan 27, 2021).Epidemiologic analyses on Ivermectin in COVID-19.Complete Guide to the Care of the COVID-19 Patient.I-RECOVER MANAGEMENT FOR LONG HAUL COVID-19.I-MASK+ PREVENTION & EARLY OUTPATIENT TREATMENT.
0 kommentar(er)
